A major receptor for nitric oxide (NO) is the cGMP-synthesizing enzyme, soluble guanylyl cyclase (sGC), but it is not known how this enzyme behaves in cells. In cerebellar cells, NO (from diethylamine NONOate) increased astrocytic cGMP with a potency (EC 50 < 20 nM) higher than that reported for purified sGC. Deactivation of NO-stimulated sGC activity, studied by trapping free NO with hemoglobin, took place within seconds (or less) rather than the minute time scale reported for the purified enzyme. Measurement of the rates of accumulation and degradation of cGMP were used to follow the activity of sGC over time. The peak activity, occurring within seconds of adding NO, was swiftly followed by desensitization to a steady-state level 8-fold lower. The same desensitizing profile was observed when the net sGC activity was increased or decreased or when cGMP breakdown was inhibited. Recovery from desensitization was relatively slow (half-time ‫؍‬ 1.5 min). When the cells were lysed, sGC desensitization was lost. Analysis of the transient cGMP response to NO in human platelets showed that sGC underwent a similar desensitization. The results indicate that, in its natural environment, sGC behaves much more like a neurotransmitter receptor than had been expected from previous enzymological studies, and that hitherto unknown sGC regulatory factors exist. Rapid sGC desensitization, in concert with variations in the rate of cGMP breakdown, provides a fundamental mechanism for shaping cellular cGMP responses and is likely to be important in decoding NO signals under physiological and pathophysiological conditions. N itric oxide (NO) performs numerous physiological functions, including relaxation of smooth muscle, inhibition of platelet aggregation, and neural communication in the brain (1, 2). A major receptor for NO is the enzyme, soluble guanylyl cyclase (sGC), which catalyzes the production of the effector molecule, cGMP from GTP (3, 4).
N
itric oxide (NO) performs numerous physiological functions, including relaxation of smooth muscle, inhibition of platelet aggregation, and neural communication in the brain (1, 2) . A major receptor for NO is the enzyme, soluble guanylyl cyclase (sGC), which catalyzes the production of the effector molecule, cGMP from GTP (3, 4) .
Compared with neurotransmitter receptors or related adenylyl and guanylyl cyclases (5, 6) , the NO receptor enzyme appears rather unremarkable. It is composed of two different subunits (␣ and ␤), but only two isoforms have been shown to exist at the protein level: the ␣1␤1 isoform, which is expressed widely, and the ␣2␤1 isoform present in human placenta (7) (8) (9) . Also, sGC appears to lack the functional complexity exhibited by related enzymes or receptors. For example, there is no established mechanism for regulation of the enzyme (e.g., by phosphorylation) and, on activation by NO, purified sGC generates cGMP at a constant rate for long periods of time (10, 11) . Furthermore, the two naturally occurring sGC isoforms possess very similar functional and pharmacological properties (9) .
How sGC responds to NO in living cells, however, has not been investigated, nor is it understood why different cells display very different patterns of NO-stimulated cGMP accumulation ranging from a transient spike-like response (12) to a more slowly developing plateau (13) . Here we have analyzed the kinetics of NO-stimulated sGC activity in intact cells. The results show that, in its natural environment, sGC performs differently from what had been assumed from previous biochemical studies. In particular, within seconds (or less), the enzyme undergoes substantial desensitization. In concert with cGMP-metabolizing enzymes, sGC desensitization enables diverse patterns of cGMP responses to NO to be generated by different cells.
Materials and Methods
Cell Preparations. Cerebellar cells from 8-day-old postnatal rats were prepared and incubated as before (14) except that hydroxyurea pretreatment, used to deplete dividing cells, was used in the initial experiments only (Fig. 2 a-d) , and the incubation medium contained 100 M nitroarginine (to prevent endogenous NO formation) but not BSA. The cells, incubated at 20 ϫ 10 6 cells͞ml, were exposed to the NO donor, diethylamine NONOate (DEA͞NO). Decomposed DEA͞NO (10 M), on its own or in the presence of 1 M DEA͞NO, did not inf luence cGMP accumulation. Washed human platelets were prepared and incubated as described (15) . When used, phosphodiesterase (PDE) inhibitors were added 10 min before DEA͞NO. cGMP was quantified by radioimmunoassay and protein by the bicinchoninic acid method. Extracellular cGMP was measured after filtering the suspensions through 0.6-m (cerebellar cells) or 0.22-m (platelets) cut-off filters. As found before (13, 14) , the amount of cGMP in the medium from cerebellar cells stimulated with DEA͞NO was negligible (1-2% of total). Values for extracellular cGMP in the platelet suspensions are given in the main text and Fig. 6 legend. NO concentrations were measured by using an electrochemical probe (World Precision Instruments, Stevenage, Herts, U.K.; Iso-NO electrode). Data are given as means Ϯ SEM (n ϭ 3-6).
sGC Activity in Lysed Cerebellar Cells. Cells were lysed in 10 mM Tris͞1 mM DTT (pH 7.4) to give the equivalent of 20 ϫ 10 6 cells͞ml, and sGC activity was assayed in the presence of 1 M DEA͞NO as before (16) except that Mg 2ϩ replaced Mn 2ϩ as cofactor, and PDE activity was inhibited by 1 mM EGTA and 1 M sildenafil. Under these conditions, a cGMP concentration (2 M) similar to that ordinarily produced after 2-min stimulation with DEA͞NO was stable over 5 min (i.e., PDE activity was zero).
Immunocytochemistry. Cerebellar cells exposed to DEA͞NO (1 M) were fixed (4% paraformaldehyde in 0.1 M phosphate buffer) for 30 min at room temperature, resuspended in buffer, Abbreviations: DEA͞NO, diethylamine NONOate; Hb, hemoglobin; NO, nitric oxide; ODQ, 1-H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-l-one; PDE, phosphodiesterase; sGC, soluble guanylyl cyclase. ‡ Present address: Statistical Sciences, SmithKline Beecham, New Frontiers Science Park North, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom. § To whom reprint requests should be addressed. E-mail: john.garthwaite@ucl.ac.uk.
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dried onto gelatin-coated slides, rehydrated with distilled water, and permeabilized with 1% Triton X-100 in Trisbuffered saline for 15 min. After rinsing (0.1% Triton X-100͞ 0.2% BSA in Tris-buffered saline), the slides were incubated with normal rabbit and horse sera for 30 min and then with the primary antibodies, sheep anti-cGMP (1:8,000, a gift from J. de Vente, University of Maastricht, the Netherlands) and mouse antiglial fibrillary acidic protein (1:800, Chemicon) overnight at 4°C. After rinsing and incubation with secondary antibodies (anti-mouse FITC and anti-sheep TRITC) for 1 h at room temperature, the slides were mounted and viewed under differential interference contrast and f luorescence optics.
Determination of vd and vs. The decline in cGMP levels occurring after deactivation of sGC in cerebellar cells and platelets was fitted to the integrated Michaelis-Menten equation:
where P o ϭ starting cGMP level, P t ϭ cGMP level at time t, and V p and K p are the apparent Michaelis-Menten constants (V max and K m ); V p , K p , and P o were found by iteration (17) . The rate of degradation,
The time courses of cGMP accumulation in cerebellar cells and platelets treated with PDE inhibitors were described by a generalized hyperbola.
where P ϭ cGMP level, a ϭ maximum cGMP level, k is a constant defining the steepness of the hyperbola, and n is a second constant required to give a gradient of zero at t ϭ 0, thereby accommodating the brief lag because of mixing and NO dissociation from the donor. Differentiating and inserting the result into the expression, dP͞dt ϭ v s Ϫ v d , gives:
from which v s was found with respect to t.
Results cGMP Accumulation in Cerebellar Cells. In the first instance, cell suspensions from the postnatal rat cerebellum were used because this brain region has low PDE activity (18) , and the dispersed cell preparation eliminates the diffusional constraints inherent in tissue slices (19) . DEA͞NO, which dissociates with a half-life of 2.1 min, was used as the source of NO. Consistent with previous observations (13), DEA͞NO caused large increases in cGMP levels. Although a mixture of cell types is present, heterogeneity of target cell cGMP responses to NO is unlikely to create complications because immunocytochemistry indicated that the increase in cGMP was localized to a discrete subpopulation of cells, the astrocytes. This applied whether the exposure to DEA͞NO was 2 min (Fig. 1 a-c) or 10 s (not illustrated) and agrees with results obtained from cerebellar slices from rats of the same age (14, 20) . The maximal effect occurred at 0.3 M DEA͞NO and the EC 50 was about 0.1 M (Fig. 2a) . The NO concentration produced in the cell suspension by 0.1 M DEA͞NO was below the detection limit of an electrochemical probe, indicating that it was less than 20 nM. To find v d , DEA͞NO was added to the cells at a supramaximal concentration (1 M) to prevent decay of NO being limiting and cGMP accumulation allowed to proceed. Then sGC activity was arrested and the fall in cGMP levels followed with time. Arrest of sGC was achieved in two ways. The first was by trapping free NO with hemoglobin (Hb) (21) at a concentration (10-50 M) that, if added 5 s beforehand, abolished the cGMP response to DEA͞NO (Fig. 2 b and c) . Whether added after 15-s (Fig. 2b ) or 125-s (Fig. 2c ) exposure to DEA͞NO, Hb caused an abrupt cessation of cGMP accumulation and, thereafter, cGMP levels declined progressively. The rate of decline followed MichaelisMenten-type kinetics, so that v d could be described operationally by the expression: v d ϭ V p P͞(K p ϩ P). Significantly, the parameters K p and V p determined by adding Hb after 125 s also described the rate of degradation at lower starting cGMP levels (Hb added at 15 s), indicating that PDE behaves in a simple substrate-linked fashion.
To check the validity of the use of Hb, we tested another strategy: inhibition of sGC with 1-H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-l-one (ODQ) (22) . The results were the same (Fig.  2d) ; moreover, the parameters determined by using the Hb method also described the decay after addition of ODQ, showing that the Hb method for determining v d is reliable.
Detailed time courses of the DEA͞NO-stimulated accumulation of cGMP showed a steep rate of rise over the initial 15 s that tailed off, giving a quasi-plateau after about 30 s (Fig. 3a) . At the plateau, by definition, the rate of cGMP degradation equals the rate of cGMP synthesis. The initial rate of cGMP degradation during the plateau was about 0.07 pmol͞10 6 cells͞s, implying that sGC was generating cGMP at the same rate. Inspection of the initial rising phase of the cGMP response, however, suggested a rate about 7-fold faster (Fig. 3a) , pointing to a large decline in enzyme activity with time. The decline could not be attributed to depletion of NO, because the NO concentration was well sustained over 2 min (0.22 Ϯ 0.03 M; n ϭ 4) and because a second dose of DEA͞NO (1 M) added after 2 min did not alter cGMP levels (data not shown).
To extract the kinetics of sGC quantitatively and more accurately, the accumulation of cGMP with time was fitted by a generalized hyperbola (Fig. 3b) . Differentiation of this expression and correcting for v d gives v s , the rate of cGMP synthesis (see Materials and Methods). Analysis of the data in this way confirmed that v s in the intact cells varied dramatically with time after addition of DEA͞NO (Fig. 3b) . Initially, it increased sharply to reach a mean peak of 0.95 Ϯ 0.11 pmol͞10 6 cells͞s after 3.8 Ϯ 0.8 s and thereafter declined rapidly to an 8-fold lower rate (0.12 Ϯ 0.08 pmol͞10 6 cells͞s) at 2 min (n ϭ 6).
In contrast to this pattern of sGC activity in intact cells, when the enzyme was assayed in lysed cells, the NO-stimulated activity was linear with time (3.5 pmol͞10 6 cells͞s; Fig. 3c ). To test the validity of the analysis of sGC activity in intact cells, therefore, and to check the possible influence of substrate depletion and͞or end-product inhibition on the kinetics of sGC, the two determinants of cGMP accumulation, v s and v d , were deliberately altered.
Effect of Varying sGC Activity. To reduce v s , ODQ was used at a concentration (0.3 M) causing a 70% reduction in the maximum cellular cGMP response to DEA͞NO. Under these conditions, the shape of the response was unchanged (Fig. 4a) . The parameters governing cGMP degradation (K p and V p ) were also the same (results not shown), indicating a lack of effect of ODQ on PDE activity. Accordingly, the derived kinetic profile of v s showed exactly the same increase and decrease seen in control cells, despite a peak activity that was 65% lower (Fig. 4b) . To increase v s , we used the allosteric sGC activator, YC-1 (23) . In the presence of YC-1 (100 M), the cGMP response to DEA͞NO was 3-fold higher than in control cells, but the time courses, again, were similar (Fig. 4a) . Because YC-1 stabilizes the binding of NO to sGC (24) and can inhibit PDE activity (25) , v d could not be determined. Therefore, v s was derived for the extreme cases of PDE activity being normal (using the v d found in control cells) and zero. In both cases, v s increased to a peak rate double that of control cells and then decreased (Fig. 3b) .
Thus, over a wide range of sGC activity resulting in a 10-fold variation in the accumulation of cGMP, the amplitude of v s changed in a predictable way, but its kinetic profile stayed the same.
Effect of Reducing PDE Activity. The aim was to eliminate v d and so determine v s directly from the experimental data. An effective way of inhibiting cGMP breakdown in the cerebellar cells was with a combination of sildenafil and rolipram. In the presence of these PDE inhibitors, the cGMP response progressively exceeded that of control cells (Fig. 5a ). Because cGMP degradation was negligible over the relevant time intervals (Fig. 5b) , v d can be taken as zero. Differentiation of the cGMP response then gives v s . The profile of v s obtained in this way superimposed accurately on the profile determined by using the usual method (Fig. 5c) .
Recovery from Desensitization. This was studied by first stimulating the cells with DEA͞NO (1 M) for 2 min to induce desensitization. Then, Hb (10 M) was added and, after various intervals, DEA͞NO was reapplied at a concentration (100 M) sufficient to overcome the effect of Hb. Analysis of the mean initial rate of rise in cGMP levels indicated that sGC was able to recover fully from desensitization within 10 min, the half-time being about 1.5 min (results not shown).
Kinetics of cGMP in Platelets.
To investigate whether sGC desensitization might be a general property of the enzyme, experiments were conducted by using human platelets. Consistent with a previous study (26) , addition of DEA͞NO (1 M) led to a transient increase in cGMP, peaking after 15 s and then falling to a much lower steady state (Fig. 6 a and c) . Under control conditions, cGMP breakdown in platelets was too fast to be measured. A combination of the PDE inhibitors, sildenafil and erythro-9-(2-hydroxy-3-nonyl)adenine greatly reduced the rate of cGMP degradation such that it was similar to the uninhibited rate observed in cerebellar cells (Fig. 6a Inset) . Under these conditions, the platelet cGMP response was transformed from a small brief transient into one that was 10-fold larger and that had a hyperbolic shape resembling that found normally in cerebellar cells (Fig. 6a) . Accordingly, deconvolution indicated that v s rose sharply and then fell, much as in cerebellar cells (Fig. 6b) .
A prediction is that if v d is increased (i.e., inhibition is removed), the transient cGMP response normally observed in platelets in the absence of PDE inhibitors should be regained. PDE catalytic efficiency, as determined in the presence of the inhibitors, was augmented by increasing V p or by decreasing K p . In both cases, a transient cGMP response similar to the measured one was obtained (Fig. 6c) , the main difference being that an increased V p (47-fold) apparently matched better the later falling and steady-state phases. The latter phase of the measured response is artifactual, however, because the cGMP in the platelet suspension after 2 min appeared to be all extracellular (equivalent to 24.0 Ϯ 1.2 pmol cGMP͞mg protein). The simulation obtained by decreasing K p (210-fold) should be more applicable, because it corresponds to removal of competitive inhibition (27) , and it appeared to be so because it undershot the later phases.
Discussion
Analysis of NO-stimulated sGC activity in intact cells has revealed several properties that were unexpected from the behavior of the enzyme in tissue homogenates or in its purified form.
First, the potency of NO in cells is greater than has been reported for purified sGC (the ␣1␤1 isoform), where an EC 50 of 250 nM was estimated (28) . However, other studies that used DEA͞NO found an EC 50 of about 100 nM (29) , suggesting a greater potency, though the resulting NO concentration was not measured directly. In the cerebellar cells, which we have found to express ␣1 and ␤1 mRNA and protein (B. Gibb & J.G., unpublished observations), NO is at least an order of magnitude more potent. This finding, which is consistent with the potency of NO to relax vascular smooth muscle (EC 50 ϭ 10 nM) (30) , helps define the physiologically relevant range of NO concentrations and suggests that current thinking about the distance over which an NO source exerts biological effects (31) will need revision.
Second, an important determinant of the dynamics of NOsGC signaling is the rate at which sGC deactivates. Measurements of the off-rate of NO from purified sGC, assuming this represents the deactivation rate, have yielded confusing results. When Hb or myoglobin was used to trap NO, the half-life of the NO-sGC complex was estimated to be about 2 min at 37°C (32, 33) . From a physiological perspective, this is very slow and difficult to reconcile with the rate at which smooth muscle recovers from NO-induced relaxation (34) . A later investigation concluded that, with GTP and Mg 2ϩ present, the half-life fell to about 5 s (35), but a different study claimed a 3-min half-life under these conditions (32) . A particularly relevant experiment was when Hb was added during the early steeply rising phase of cGMP accumulation in the cerebellar cells (Fig. 2b ). Just 5 s later, cGMP was not only significantly less than in control cells but was at the level predicted should the amount of cGMP at this time be governed solely by PDE activity (i.e., residual sGC activity was zero). Other experiments in which Hb was added later gave concordant results. Hence, in living cells, sGC deactivation occurs with a half-life of no more than a few seconds and possibly much less, allowing sGC to respond dynamically to fluctuations in NO concentration.
The third and most surprising result was that NO-stimulated sGC activity, both in rat cerebellar cells and in human platelets, underwent rapid desensitization. This phenomenon is unlikely to be peculiar to exogenously added NO, because the kinetics of cGMP accumulation observed in the cerebellar cells in the present study is very similar to those occurring in the same cells when endogenous NO production is provoked (13, 14, 19) . Consistent with the type of desensitization we describe also existing in vivo is the finding that the hypotensive effects of nitrovasodilators are enhanced when endogenous NO formation is inhibited acutely, an effect attributed from in vitro experiments, to reflect alterations in the sensitivity of smooth muscle sGC to NO (36) .
Desensitization appeared to curtail sGC activity within a few seconds of addition of the NO source but because these very early kinetics will also be influenced by the rate of dissociation of NO from the donor, desensitization may well set in earlier.
Recovery from desensitization, by comparison, was slow, taking several minutes to be complete. Fast entry into and slow exit from the desensitized state are characteristics classically associated with neurotransmitter receptors (37) . The kinetics of onset and recovery clearly distinguishes sGC desensitization recorded in our experiments from sGC down-regulation (sometimes also called ''desensitization'') typically seen after chronic (hoursdays) exposure to NO-releasing agents and which probably ref lects destabilization of subunit mRNA and͞or protein (38 -40) .
The mechanism of sGC desensitization remains unknown. Depletion of substrate (GTP) or direct end-product inhibition (by cGMP) appear not to participate because the desensitization kinetics was little changed despite variations of 6-fold in sGC activity and 10-fold in cGMP levels. That sGC failed to desensitize when assayed in lysed cerebellar cells agrees with numerous previous studies (10, 11, 16) and suggests the existence of a cellular factor that loses its activity (possibly by dilution) in cell-free preparations. Because sGC activity in the lysed cells was about 4-fold higher than the peak activity recorded in intact cells (Fig. 3 b and c) , the endogenous factor could function as an inhibitor. A previous study has suggested that there is a protein inhibitor of sGC in bovine lung (41) , although it remains to be characterized. Recently, Ca 2ϩ was found to inhibit sGC (42) , but only at concentrations orders of magnitude higher than those normally found free in the cytosol. Accordingly, sGC desensitization in cerebellar cells was unaffected by removal of extra- Functionally, desensitization of sGC works in concert with PDE activity to shape the cellular cGMP response to NO. That is, as PDE activity differs (43) , sGC densitization imposes varying patterns of cGMP accumulation, ranging from a brief low-amplitude transient (with high PDE activity) to a large sustained plateau (with low PDE activity) or a mixture of the two (Fig. 6d) . This range of behavior encompasses all the shapes of cGMP response to NO that we have encountered in the literature. The varying temporal and amplitude characteristics are expected to be important in the differential selection of downstream transduction pathways [e.g., high-affinity cGMPdependent protein kinases vs. low affinity cGMP-gated ion channels (44) ].
In conclusion, NO-stimulated sGC activity within a cellular environment is more complex than previously assumed, implying the existence of hitherto unknown regulatory factors. The rapid on-and off-kinetics and the desensitizing profile of activity indicate that the properties of sGC are much more akin to those of a neurotransmitter receptor than previous evidence had suggested. The possibility that alterations in sGC regulation contribute to clinical conditions associated with abnormal tissue responsiveness to NO, such as vascular disorders (45) and erectile dysfunction (46) , merits investigation.
